Telix Pharmaceuticals has announced an asset purchase agreement with antibody engineering firm ImaginAb, marking the expansion of its capabilities in precision medicine and therapeutic innovation.
The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary biologics technology platform, and a research facility specialising in protein engineering and discovery, Telix said in a media release.
The deal introduces a range of early-stage drug candidates targeting high-value areas such as DLL3 and integrin ?v?6, along with several additional targets currently in discovery stages.
These assets align closely with Telix’s existing therapeutics pipeline, providing opportunities to address clinical needs in new therapeutic areas.
The proprietary intellectual property employs advanced antibody formats designed for precise cancer targeting, enabling rapid tumour uptake and efficient blood clearance.
This technology is anticipated to enhance tumour imaging and treatment using a wide array of radioisotopes, including alpha emitters.
The acquisition also includes a cutting-edge research facility in California. This center is staffed with a team of experts in discovery, protein engineering, and radiopharmaceutical development, equipping Telix with enhanced in-house capabilities for antibody engineering and preclinical development.
This novel biologics platform is expected to accelerate the creation of next-generation precision medicines and therapeutic products beyond Telix’s current clinical-stage portfolio.
Richard Valeix, CEO of Therapeutics at Telix, highlighted the strategic significance of the acquisition, stating, “The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets, and a talented team of subject matter experts will enhance Telix’s research and innovation capability now and into the future. This acquisition will enable Telix to explore new disease areas with state-of-the-art radiotherapeutic technology.”
Dr Anna M Wu, co-founder and board member of ImaginAb, underscored the potential of the collaboration, commenting, “As the radiopharmaceutical sector gains momentum there is a significant need for targeting agents to be more selective, deliver less off-target radiation, and better match the pharmacology and radiobiology of a given radionuclide.”
“The team’s deep expertise in antibody engineering and the resulting development of a valuable, proprietary platform technology has led to clinical proof-of-concept. Telix is the right partner to unlock the future therapeutic potential of this platform.”
